San Diego-based Viking Therapeutics marked alone as a serious competitor within the weight loss drug market in February soon after revealing promising data from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when provided as a weekly injection As well as in March the company unveiled